Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia.
Yirga Legesse NiriayoKabaye Kumela GoroKidu GideyMulugeta Tarekegn AngamoPublished in: BioMed research international (2019)
Although majority of patients were receiving ACEIs, only about one-third were using optimal dosage. Valvular heart disease and NYHA class III were negatively associated with the use of ACEIs while previous hospitalization for heart failure, old age, diuretic use, and diuretic dose were predictors of suboptimal dosing of ACEIs. Therefore, more effort needs to be done to minimize the potentially modifiable risk factors of suboptimal use of ACEIs therapy in heart failure patients.
Keyphrases
- ejection fraction
- angiotensin converting enzyme
- heart failure
- risk factors
- end stage renal disease
- angiotensin ii
- acute heart failure
- newly diagnosed
- atrial fibrillation
- chronic kidney disease
- prognostic factors
- pulmonary hypertension
- peritoneal dialysis
- stem cells
- patient reported outcomes
- cell therapy
- mesenchymal stem cells